Published in Neurotox Res on February 20, 2009
Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach. Curr Drug Targets (2011) 1.53
Natural products from ethnodirected studies: revisiting the ethnobiology of the zombie poison. Evid Based Complement Alternat Med (2011) 1.09
A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. Parkinsonism Relat Disord (2010) 0.92
The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate. Evid Based Complement Alternat Med (2012) 0.78
Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor. Front Syst Neurosci (2011) 0.78
Effects of five Ayurvedic herbs on locomotor behaviour in a Drosophila melanogaster Parkinson's disease model. Phytother Res (2014) 0.77
Therapies for Parkinson's diseases: alternatives to current pharmacological interventions. J Neural Transm (Vienna) (2016) 0.75
Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology (2004) 3.52
Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci (2006) 2.14
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Exp Neurol (2010) 1.44
Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata. Exp Neurol (2003) 1.38
Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care. EPMA J (2011) 1.17
Morphine-conditioned single-trial place preference: role of nucleus accumbens shell dopamine receptors in acquisition, but not expression. Psychopharmacology (Berl) (2006) 1.16
Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc Natl Acad Sci U S A (2013) 1.09
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res (2007) 1.09
Coumarins from Opopanax chironium. New dihydrofuranocoumarins and differential induction of apoptosis by imperatorin and heraclenin. J Nat Prod (2004) 1.06
Piecing together the puzzle of acetaldehyde as a neuroactive agent. Neurosci Biobehav Rev (2011) 1.05
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci (2005) 1.02
Antibacterial galloylated alkylphloroglucinol glucosides from myrtle (Myrtus communis). J Nat Prod (2006) 1.01
Nicotine-conditioned single-trial place preference: selective role of nucleus accumbens shell dopamine D1 receptors in acquisition. Psychopharmacology (Berl) (2005) 0.99
Oligomeric acylphloroglucinols from myrtle (Myrtus communis). J Nat Prod (2002) 0.99
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem (2009) 0.98
Ethanol-induced extracellular signal regulated kinase: role of dopamine D1 receptors. Alcohol Clin Exp Res (2009) 0.95
Arzanol, an anti-inflammatory and anti-HIV-1 phloroglucinol alpha-Pyrone from Helichrysum italicum ssp. microphyllum. J Nat Prod (2007) 0.95
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward. Neuropharmacology (2012) 0.95
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem (2008) 0.93
Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol (2002) 0.92
SERCA-inhibiting activity of C-19 terpenolides from Thapsia garganica and their possible biogenesis. J Nat Prod (2005) 0.92
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. Brain (2012) 0.91
Jatrophane diterpenes as P-glycoprotein inhibitors. First insights of structure-activity relationships and discovery of a new, powerful lead. J Med Chem (2003) 0.90
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res (2003) 0.88
Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins. Neurotox Res (2010) 0.87
Deuterated matrix-assisted laser desorption ionization matrix uncovers masked mass spectrometry imaging signals of small molecules. Anal Chem (2012) 0.87
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse (2002) 0.87
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur J Med Chem (2003) 0.87
Acetaldehyde elicits ERK phosphorylation in the rat nucleus accumbens and extended amygdala. Synapse (2010) 0.86
Antioxidant activity of capsinoids. J Agric Food Chem (2002) 0.85
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology (2009) 0.85
Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology (2004) 0.85
Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol (2004) 0.84
Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse (2001) 0.84
Antioxidant activity of oligomeric acylphloroglucinols from Myrtus communis L. Free Radic Res (2003) 0.84
Chemopreventive and antioxidant activity of the chamazulene-rich essential oil obtained from Artemisia arborescens L. growing on the Isle of La Maddalena, Sardinia, Italy. Chem Biodivers (2013) 0.84
Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. NeuroRehabilitation (2012) 0.84
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse (2007) 0.83
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse (2008) 0.83
Hypericum hircinum L. components as new single-molecule inhibitors of both HIV-1 reverse transcriptase-associated DNA polymerase and ribonuclease H activities. Pathog Dis (2013) 0.83
Role of dopamine D1 receptors and extracellular signal regulated kinase in the motivational properties of acetaldehyde as assessed by place preference conditioning. Alcohol Clin Exp Res (2010) 0.83
Sensitization to caffeine and cross-sensitization to amphetamine: influence of individual response to caffeine. Behav Brain Res (2006) 0.82
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons. Exp Neurol (2013) 0.82
Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity. Bioorg Med Chem (2004) 0.82
Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats. Addict Biol (2013) 0.82
Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. Neurotox Res (2009) 0.81
The occurrence of phenyl propanoid glycosides in endemic Teucrium species. Nat Prod Res (2007) 0.81
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol (2007) 0.81
Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J (2010) 0.81
Antimycobacterial coumarins from the sardinian giant fennel (Ferula communis). J Nat Prod (2004) 0.81
Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behav Pharmacol (2009) 0.81
Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. Eur J Pharmacol (2003) 0.81
Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats. Exp Brain Res (2009) 0.81
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions. J Neurochem (2014) 0.81
Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons. J Neurochem (2006) 0.80
Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity. Psychoneuroendocrinology (2010) 0.80
Intensive rehabilitation treatment in parkinsonian patients with dyskinesias: a preliminary study with 6-month followup. Parkinsons Dis (2012) 0.80
Withania somnifera prevents acquisition and expression of morphine-elicited conditioned place preference. Behav Pharmacol (2013) 0.80
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease? Behav Pharmacol (2006) 0.80
Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release. Neuropsychopharmacology (2003) 0.80
Pterocarpans from Bituminaria morisiana and Bituminaria bituminosa. Phytochemistry (2003) 0.80
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology (2003) 0.80
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists. Neurotox Res (2013) 0.80
Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases. Neurotherapeutics (2009) 0.80
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats. Exp Brain Res (2007) 0.80